Co to jest strona internetowa?

Central European BioForum, Warsaw (2026)

19/04/2026

🔴 CEBioForum 2026 | Special Announcement

We are honored to welcome Katarzyna Pełczyńska-Nałęcz, Minister of Funds and Regional Policy, as our Guest of Honor at the Opening Ceremony of .

CEBioForum has for over 20 years brought together innovators, business leaders, investors, and policymakers—creating a unique space where science meets capital and strategy.

🇵🇱 This is exactly where public policy becomes critical.

As the Minister responsible for European and national development funds, Katarzyna Pełczyńska-Nałęcz plays a key role in shaping the landscape in Poland and across CEE - supporting R&D, infrastructure, and high-growth sectors such as , medtech, and health innovation.

💡 At a time when:

▶️ access to capital defines the pace of innovation

▶️ public-private alignment becomes a competitive advantage

▶️ and Europe is strengthening its strategic autonomy in life sciences

— this perspective is more important than ever.

Her presence at the Opening Ceremony highlights the growing importance of policy, funding, and strategic direction in building a strong ecosystem.

📍 Join us in Warsaw, April 22–23

Be part of the conversations shaping the future of biotech in Central & Eastern Europe.

🔗 https://cebioforum.com/cebioforum2026_tickets/

17/04/2026

❓ Can we make drug development smarter — and finally reduce the 93% failure rate?

The gap between lab discoveries and clinical success remains one of the biggest challenges in . With increasing pressure on efficiency, cost, and predictability, the need for more advanced and translationally relevant testing approaches has never been greater.

At , this panel will explore how science is evolving to make preclinical research more predictive, reliable, and aligned with clinical outcomes.

▶️ “Smarter Science: Quo Vadis Testing” will focus on:

🧬 improving the predictive value of preclinical models

🧬 new approach methodologies (NAMs) and translational platforms

🧬 balancing innovation with regulatory expectations

🧬 increasing efficiency without compromising scientific rigor

🎤 Moderator – Przemko Tylzanowski (KU Lueven, Medical University of Lublin)

👥 Speakers:

▪️ Marta Gajewska (SGGW / PolLASA)

▪️ Piotr Podlasz (University of Warmia and Mazury)

▪️ Ewa Sokolowska (Transpharmation Poland)

▪️ Tomasz Trombik (Medical University of Lublin)

💡 This panel brings together leading experts in preclinical research and translational science. With deep experience in animal models, neuroscience, oncology, and experimental medicine — spanning both academia and industry — the speakers develop and apply advanced platforms to better predict clinical outcomes. Their work directly addresses one of the most critical bottlenecks in drug development: turning promising science into effective therapies.

This session is essential for researchers, biotech companies, and R&D leaders working to build more efficient and reliable innovation pipelines.

🚨 Last call — secure your spot now:

👉 https://cebioforum.com/cebioforum2026_tickets/

📍 Warsaw | April 22–23, 2026

16/04/2026

❓ Can Central & Northern Europe become a true biotech powerhouse — or will fragmentation hold it back?

The region is gaining momentum as a competitive player in the global landscape — combining strong science, growing innovation capacity, and increasingly active ecosystems. Yet challenges in scaling, commercialization, and cross-border collaboration continue to slow down its full potential.

At , this panel will examine how Central and Northern Europe can move from promise to global impact.

▶️ “Central and Northern Europe Biotech Landscape: Opportunities for Growth” will explore:

🧬 how the region positions itself in the global biotech race

🧬 key advantages vs structural gaps in funding and scaling

🧬 bridging the gap between research and market application

🧬 strengthening cross-border collaboration and ecosystem integration

🎤 Moderator – Aleksandra Kubica-Misztal

👥 Speakers:

▪️ Magdalena Kołodziejska (National Centre for Research and Development – NCBR)

▪️ Petra Kinzlová (Prague.bio)

▪️ Iva Machová (i&i Prague)

▪️ Adam Pustelnik (City of Łódź)

▪️ Agne Vaitkeviciene (Avaitis / LithuaniaBIO)

💡 This panel brings together leaders shaping biotech ecosystems across the region. With experience spanning public sector strategy, international collaboration, technology transfer, investment support, and company building, the speakers actively develop frameworks that enable innovation to scale. Their perspectives reflect both policy-level and operational realities of building competitive biotech hubs in Central and Northern Europe.

This session is essential for , policymakers, and ecosystem builders working to unlock the next phase of and regional growth.

🚨 Last call — secure your spot now:

👉 https://cebioforum.com/cebioforum2026_tickets/

📍 Warsaw | April 22–23, 2026

15/04/2026

🚀 Endolink joins as a Silver Partner – Advancing Endovascular Innovation! 🔬💡

We’re excited to welcome Endolink as a Silver Partner of ! 🎉

Endolink is a specialized company focused on delivering innovative solutions for endovascular treatment, particularly in the management of aneurysms and dissections of the abdominal and thoracic aorta. With a strong foundation built on , experience, and carefully selected technologies, the company supports clinicians with advanced tools for minimally invasive, life-saving procedures.

Mission & Vision

Endolink’s mission is to provide modern solutions that expand possibilities in endovascular therapy. The company aims to become a trusted provider of unique and highly innovative medical devices, strengthening the between patients, physicians, and technology through quality and reliability.

About the Company

Operating in the medical device market since 2009, Endolink has continuously developed its portfolio — from vascular grafts to advanced stentgrafts and specialized endovascular systems. Today, the company focuses on distributing highly specialized, niche products that often have no direct competition, supporting cutting-edge treatment of complex conditions.

At the intersection of medtech, , and clinical innovation, Endolink reflects the direction of modern healthcare — toward precision, minimally invasive therapies, and improved patient outcomes.

📅 Join us on April 22–23, 2026

📍 CIC Warsaw, Poland

Meet innovators, clinicians, and industry shaping the future of biotech and medtech in Central and Eastern Europe.

🔗 Secure your spot and be part of the conversation!

https://cebioforum.com/cebioforum2026_tickets/

15/04/2026

❓ Can great science speak for itself — or does need better to succeed?

In life sciences, breakthrough innovation alone is not enough. To attract partners, , and talent, companies must translate complex into narratives that are both credible and compelling.

At , this panel will explore how biotech and pharma organizations can communicate innovation effectively — across audiences, markets, and stages of growth.

▶️ “Biotech in Translation: How to Tell the Story of ” will focus on:

🧬 translating complex science into clear, impactful messages

🧬 building trust and credibility across

🧬 aligning with business development and growth

🧬 how storytelling shapes perception, partnerships, and market success

🎤 Moderator – Jakub Knurek (Mabion)

👥 Speakers:

▪️ Maryam Daneshpour (Biotech & Pharma Market Research)

▪️ Ewa Kasprzak (Twist Bioscience)

▪️ Mariusz Popin (HAYS Poland)

▪️ Bilyana Petrova (JPP – Life Sciences Marketing & BD)

💡 This panel brings together experts operating at the intersection of science, business, and communication. With backgrounds spanning biotech R&D, market research, executive recruitment, and strategic marketing, the speakers work daily on translating scientific value into real-world outcomes — from positioning and employer branding to development. Their combined experience shows how effective communication directly impacts growth, trust, and ecosystem visibility.

This session is essential for founders, BD leaders, and communication professionals looking to elevate how innovation is understood and valued.

🚨 Last call — secure your spot now:

👉 https://cebioforum.com/cebioforum2026_tickets/

📍 Warsaw | April 22–23, 2026

14/04/2026

⭐ Important Announcement! ⭐

We are pleased to announce that in Lodz - Central Poland has joined as a Silver Partner. The conference will bring together from biotechnology, pharma, medtech, and investment communities to exchange knowledge and explore collaboration opportunities across the life science .

Invest in Łódź is the official investor support office of the City of Łódź, at the centre of the local ecosystem. The organisation supports companies at every stage of establishing and scaling operations in Łódź – providing direct access to the right partners, talent, infrastructure, and public stakeholders, while also supporting employer branding, with a strong focus on LifeSciences.

Based on sector research, the LifeSciences ecosystem in Łódź has been defined across three interconnected layers:

⚛️ R&D core (BioTech & BioChem) – 200+ entities

⚛️ key industries (MedTech, PharmaTech, Beauty, FoodTech) – 1,600+ companies

⚛️ supporting ecosystem – ~14,000 entities

Together, they form one of the largest life science hubs in Poland, supported by:

⚛️ a strong laboratory base and advanced R&D infrastructure

⚛️ ~2,800 in the scientific core

⚛️ ~13,500 across key industries

⚛️ ~70,000 professionals in the wider

Meet Invest in Łódź team at to explore collaboration opportunities and discover how Łódź can support your next LifeSciences project.

🚨 Last call — secure your spot now:

👉 https://cebioforum.com/cebioforum2026_tickets/

14/04/2026

❓ Is CEE biotech truly investable — or still misunderstood by global capital?

Central and Eastern Europe is rapidly emerging as a high-potential destination for investment — combining strong scientific talent, capital efficiency, and access to undervalued innovation. Yet despite these advantages, structural barriers continue to limit capital inflow and prevent companies from scaling at pace.

At , this panel will take a candid, investor-first perspective on what it really takes to unlock venture capital across the region.

▶️ “Investing in Biotech: Opportunities & Barriers” will explore:

🧬 what makes CEE biotech companies investable in practice

🧬 risk vs return expectations from an perspective

🧬 key from early-stage funding to exit

🧬 how companies can be actively de-risked to attract capital

🎤 Moderator – Robert Rzemiński (CELON Pharma)

👥 Speakers:

▪️ Tobiasz Jankowski (MCI Capital)

▪️ Wojciech Kula (Axcellant)

▪️ Paweł Przewięźlikowski (Ryvu Therapeutics)

▪️ Piotr Godlewski (FGGH IP)

💡 Our speakers bring a uniquely cross-sectional perspective on the CEE . With decades of experience spanning pharmaceutical development, , private equity, intellectual property, clinical research, and company building, they have collectively shaped investment strategies, scaled biotech , and influenced innovation policy across the region. Their combined track record covers the full lifecycle — from early-stage financing and IP strategy to clinical development and global partnerships.

This is a must-attend discussion for , founders, and decision-makers looking to understand — and capitalize on — the next wave of growth.

🚨 Last call — secure your spot now:

👉 https://cebioforum.com/cebioforum2026_tickets/

📍 Warsaw | April 22–23, 2026

13/04/2026

❓ Looking to better understand how to secure funding for breakthrough biotech innovation?

We’re proud to announce that National Centre for Research and Development (NCBR) joins as a Golden Partner — a key institution supporting the growth of the Polish biotech .

ℹ️ During the conference, NCBR will host a dedicated thematic roundtable focused on the STEP instrument, offering practical insights for innovators and companies navigating public funding opportunities.

💡 What will be covered?

▶️ Who is designed for

▶️ Key thematic areas of the instrument

▶️ What makes STEP unique

▶️ What to consider before applying

▶️ The most common in funding applications

The session will be led by Małgorzata Ziemińska, Director of the Commercialization Department at NCBR.

💡 The STEP Biotechnologies calls are implemented under the European Funds for a Smart Economy programme. The STEP initiative is part of the European Union’s broader effort to strengthen strategic autonomy in critical technologies.

⏩ The National Centre for Research and Development will officially launch the STEP Biotechnologies calls on May 8. Critical technologies and their value chains will be developed through R&D projects — covering industrial research and experimental development or development work only — funded by NCBR across two pathways:

🅰️ Path A – for R&D projects introducing an innovative, state-of-the-art, or breakthrough component to the EU internal market with significant economic potential (at least two of these criteria must be met)

🅱️ Path B – for R&D projects contributing to reducing or eliminating the European Union’s strategic dependencies

📆 The application process will open on July 6 and run until September 7, 2026 for Path A, and from July 13 to September 16, 2026 for Path B.

This is a must-attend discussion for anyone planning to scale through public funding mechanisms and better understand how to successfully apply!

📍 Join us on April 22–23 in Warsaw and connect with institutions shaping the future of .

🔗 Secure your tickets now! https://cebioforum.com/cebioforum2026_tickets/

13/04/2026

❓ Is European life sciences venture capital ready for what’s coming next?

Europe produces outstanding science — but scaling companies remains a systemic challenge. From fragmented funding landscapes to limited late-stage capital, many promising ventures struggle to move beyond early development and compete globally.

At , this panel will take a hard, practical look at what’s working — and what clearly isn’t — in today’s VC .

▶️ “Effective Venture Capital in European Life Sciences: What’s Working, What’s Broken, and What’s Next?” will bring together leading investors to unpack:

🧬 structural gaps from Seed to Series B

🧬 capital efficiency in a high-risk, long-cycle sector

🧬 the evolving role of VCs in company building and scientific translation

🧬 what Europe must change to compete globally by 2030

🎤 Moderator - Karolina Jarosińska, Managing Director, ExecMind

👥 Speakers:

▪️Marios Nicolettis (Moondust Ventures)

▪️ Katarzyna Wójcik Bąkowska (Wolf Theiss)

▪️ Aleksander Kłósek (YouNick Mint)

▪️ Robert Aleksandrowicz (Twiti Investments)

▪️ Bernhard Nussbaumer (ACMIT GmbH)

This is a must-attend discussion for , founders, and ecosystem leaders shaping the future of and European innovation.

🚨 Last call — secure your spot now:

👉 https://cebioforum.com/cebioforum2026_tickets/

📍 Warsaw | April 22–23, 2026

06/02/2026

💰 Funding Meets Science: CEBioForum Awards, Horizon Europe & Future Tech Poland

The newest edition of the CEBioForum is here, packed with key breakthroughs, policy shifts, and funding opportunities shaping Europe’s life sciences ecosystem.

Here’s what you’ll find:

✅ CEBioForum Awards 2026 – Registrations now open! 🏆

Celebrating the most impactful innovators, collaborations, leaders — and Impact Investors driving measurable biotech growth. Apply by March 22.

✅ Big funding momentum in Europe 💰🇪🇺

From €14B under Horizon Europe 2026–2027 to the launch of Future Tech Poland, a PLN 1.5B fund-of-funds backed by BGK and the European Investment Fund (EIF) to scale high-growth tech companies.

✅ Breakthrough science enters the clinic 🔬

The FDA clears the first human trial of epigenetic reprogramming therapy, with Life Biosciences testing a novel approach to age-related eye diseases.

✅ Leadership shaping Poland’s biomedical ecosystem 🇵🇱

Michał Fendler concludes his 19-month term at the Medical Research Agency (ABM), leaving behind record funding levels, major oncology and translational research programs, and a strengthened clinical research infrastructure engaging over 90,000 patients.

📩 Stay ahead of funding, science, and strategy — read the full newsletter now!
https://www.linkedin.com/posts/central-european-bioforum_funding-newsletter-cebioforum2026-activity-7423976037966839808-SMf4?utm_source=share&utm_medium=member_desktop&rcm=ACoAAEQ2TKsBDfGBEaDQvZgOoKUCEC5NIUgkw0A

04/02/2026

🎉 CEBioForum Awards 2026 – Submissions Are Now Open! 🎉

Every breakthrough in has a story behind it — a bold idea, a dedicated team, a strategic decision that helped science move forward. The Awards 2026 are once again opening the stage for those stories to be seen, heard, and celebrated by the life sciences community.

By taking part in the Awards, you join a plebiscite that recognizes excellence across the entire biotech - from innovation and collaboration to leadership and investment impact.

🏆 CEBioForum Awards 2026 Categories:

▶️ Innovative Start-Up – for young transforming breakthrough science into market-ready solutions

▶️ R&D Collaboration – for successfully bridging academia, clinicians, and industry

▶️ Most Influencing Person in Biotechnology – honoring shaping the direction of life sciences

▶️ Jury Award – a special distinction for truly outstanding, cross-cutting

⭐ Impact Investor *(NEW CATEGORY)* – recognizing investors who, in the past year, played a key role in advancing the sector by supporting the most promising projects, companies, and transactions, contributing to measurable growth and ecosystem development

The Impact Investor category shines a spotlight on a critical yet often unseen force behind innovation — smart capital combined with long-term vision.

🏆 Why take part?

⭕ Gain recognition among industry leaders, scientists, and decision-makers

⭕ Strengthen your visibility within the international life sciences ecosystem

⭕ Celebrate your success during the exclusive CEBioForum Awards Banquet

📅 Submissions are open until March 22

Take part in the CEBioForum Awards 2026 and make your impact visible — on stage, among peers, and at the heart of the biotech community.

🔗 Submit your application or nomination: https://cebioforum.com/cebioforum2026_awards/

02/02/2026

🚨 [Keynote] Our Future is Biotech: Why this $8 trillion industry is just getting started - with Andrew Craig 🚨

We are delighted to announce Andrew Craig as a Keynote Speaker at 🔴

Andrew is a best-selling British author, entrepreneur, investment professional, and founder of personal finance business Plain English Finance.

👤 Andrew began his career at SBC Warburg in the late 1990s. Since then, he has held various senior equity roles at leading investment banks, both in London and New York. From 2015 to 2021, he was a partner at WG Partners LLP, a London-based investment bank specialising in and life sciences.

During his career he has met with the senior management teams of over one thousand companies and with several hundred professional and regularly been involved in high profile stock market transactions.

📈 These have included the Kingdom of Sweden’s sales of Nordea Bank AB in 2013 (totalling $7.6 billion) and the stock market flotation of several dozen companies including the likes of: easyJet, HMV, Burberry, Campari, Carluccio’s, the Carbon Trust, and [lastminute.com](http://lastminute.com/). In his time at WG Partners he acted for more than 60 companies.

📚 Andrew’s first book, *How to Own the World*, has been one of the top-selling personal finance books in the UK for several years, and currently enjoys thousands of reviews across Amazon, Audible and Goodreads. His third book “*Our Future is Biotech”* published globally in August 2024, explores how biotechnology is poised to address critical global in health, sustainability, and economic development.

🎙️ Since founding Plain English Finance, Andrew has appeared in numerous national and specialist financial including: The Telegraph, The Financial Times, The Mail on Sunday, The Mirror, City A.M., The Spectator, Shares and MoneyWeek magazines, YourMoney, This is Money and Money Observer.

👏 Through his writing and public speaking, he advocates for greater public understanding of both and , emphasising the importance of accessible education in both fields.

🗓 Date: April 22–23, 2026

📍 Location: Warsaw, Poland

💡 is the meeting point for leaders, innovators, investors, and scientists shaping the future of biotechnology in Central & Eastern Europe and beyond. Andrew Craig’s keynote will offer a compelling perspective on why biotechnology is not only a scientific revolution - but a defining economic opportunity of our time.

👉 Join us and be part of the ecosystem

🔗 Register here: https://cebioforum.com/cebioforum2026/

Central European BioForum

19/04/2026

17/04/2026

16/04/2026

15/04/2026

15/04/2026

14/04/2026

14/04/2026

13/04/2026

13/04/2026

06/02/2026

04/02/2026

02/02/2026

Adres

Strona Internetowa

Ostrzeżenia

Skontaktuj Się Z Firmę

Skróty

Udostępnij

Kategoria